When would you consider aspirin for long term management of unprovoked VTE after initial therapeutic anticoagulation?
The WARFASA study suggests some benefit of aspirin in preventing recurrence. Would you consider it only in high bleeding risk patients, or even consider it for those reluctant to be on long-term anticoagulation?
1 Answer
Mednet MemberInvited Expert
Hematology · Oregon Health & Science University
Answered on
The WARFASA trial randomly assigned patients with first unprovoked VTE who had completed 6-18 months of anticoagulation to 2 additional years of aspirin versus placebo. While the study demonstrated a 40% reduction in recurrent thrombotic events, the rates of VTE in those receiving aspirin were still...
Join for free or sign in to see the full answer